SEngine Precision Medicine receives $10 million in Series A+ financing
SEngine Precision Medicine is an American cancer-targeted drug developer. It uses sonic pipetting technology and uses the new testing platform PARIS to develop personalized drugs for each cancer patient; including small molecule inhibitors, etc. Get personalized advice. SEngine Precision Medicine recently announced the completion of a $10 million Series A+ financing led by Washington Research […]
SEngine Precision Medicine receives $10 million in Series A+ financing Read More »